MCID: BNG032
MIFTS: 53

Benign Mesothelioma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Benign Mesothelioma

MalaCards integrated aliases for Benign Mesothelioma:

Name: Benign Mesothelioma 12 15
Mesothelioma 44 17 70 32
Benign Tumor of Mesothelium 12
Adenomatoid Tumor 70

Classifications:



External Ids:

Disease Ontology 12 DOID:2645
MeSH 44 D008654
NCIt 50 C3234
SNOMED-CT 67 154491004
ICD10 32 C45 C45.9
UMLS 70 C0025500 C0206675 C1290375

Summaries for Benign Mesothelioma

Disease Ontology : 12 A cell type benign neoplasm that has material basis in mesothelium.

MalaCards based summary : Benign Mesothelioma, also known as mesothelioma, is related to malignant peritoneal mesothelioma and peritoneal mesothelioma, and has symptoms including snoring and coughing. An important gene associated with Benign Mesothelioma is WT1 (WT1 Transcription Factor), and among its related pathways/superpathways are Keratinization and Cytoskeletal Signaling. The drugs Vorinostat and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include testis, lung and t cells, and related phenotypes are cardiovascular system and digestive/alimentary

Wikipedia : 73 Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the... more...

Related Diseases for Benign Mesothelioma

Diseases in the Benign Mesothelioma family:

Mesothelioma, Malignant Benign Intermediate Mesothelioma

Diseases related to Benign Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 980)
# Related Disease Score Top Affiliating Genes
1 malignant peritoneal mesothelioma 32.6 NF2 CDKN2A
2 peritoneal mesothelioma 32.2 WT1 THBD NF2 CEACAM5 CDKN2A CALB2
3 malignant epithelial mesothelioma 32.2 THBD CEACAM5 CALB2
4 pericardial mesothelioma 32.1 VIM KRT19 CALB2
5 malignant biphasic mesothelioma 32.0 WT1 THBD MSLN KRT5 CALB2
6 asbestosis 32.0 WT1 THBD MSLN CALB2
7 lymphohistiocytoid mesothelioma 31.9 THBD CEACAM5 CDKN2A CALB2
8 sarcomatoid mesothelioma 31.3 WT1 VIM THBD PDPN NKX2-1 MSLN
9 pleural disease 31.1 NF2 MSLN CEACAM5 CALB2
10 malignant pleural mesothelioma 31.0 WT1 THBD PDPN NKX2-1 NF2 MTAP
11 adenocarcinoma 30.9 NKX2-1 KRT7 KRT20 CEACAM5 CDKN2A
12 lung sarcoma 30.5 NKX2-1 CALB2
13 lung sarcomatoid carcinoma 30.5 THBD NKX2-1 CALB2
14 spindle cell sarcoma 30.5 VIM NF2 KRT7
15 intestinal obstruction 30.5 KRT7 KRT20 CEACAM5
16 pseudomyxoma peritonei 30.5 KRT7 KRT20 CEACAM5
17 cystic lymphangioma 30.3 PECAM1 PDPN CALB2
18 endosalpingiosis 30.2 WT1 KRT7 CALB2
19 appendix adenocarcinoma 30.2 KRT7 KRT20
20 fibroma 30.2 VIM PECAM1 CALB2
21 pericardial tuberculosis 30.2 CEACAM5 CALB2
22 pleural cancer 30.1 WT1 NF2 MTAP MSLN KRT5 CDKN2A
23 neurilemmoma 30.1 VIM NF2 CALB2
24 small cell cancer of the lung 30.1 NKX2-1 KRT7 KRT20 CEACAM5 CDKN2A
25 ovarian cystadenocarcinoma 30.1 CEACAM5 CDKN2A CALB2
26 ovary adenocarcinoma 30.0 WT1 KRT7 CEACAM5 CDKN2A
27 sarcoma, synovial 30.0 WT1 VIM KRT7 KRT19 CALB2
28 squamous cell carcinoma 30.0 PDPN KRT7 KRT19 CEACAM5 CDKN2A
29 secretory meningioma 30.0 VIM NF2 KRT7 CEACAM5
30 bronchiolo-alveolar adenocarcinoma 30.0 NKX2-1 KRT7 KRT20 CEACAM5
31 lung squamous cell carcinoma 29.9 PDPN KRT19 GPC3 CDKN2A
32 pneumothorax 29.9 VIM NKX2-1 CALB2
33 wilms tumor 1 29.9 WT1 VIM PDPN NKX2-1 KRT7 GPC3
34 cystadenocarcinoma 29.9 VIM PDPN KRT7 CEACAM5
35 small cell carcinoma 29.9 NKX2-1 KRT7 KRT20 KRT19 CDKN2A
36 mesothelioma, malignant 29.9 WT1 VIM THBD PDPN NKX2-1 NF2
37 papillary carcinoma 29.9 NKX2-1 KRT7 KRT20 KRT19 CALB2
38 trachea carcinoma 29.9 KRT7 KRT5
39 carcinosarcoma 29.8 VIM KRT7 CDKN2A CALB2
40 cystadenoma 29.8 KRT7 KRT20 CEACAM5 CALB2
41 angiosarcoma 29.8 VIM PECAM1 PDPN KRT7 CALB2
42 meningioma, familial 29.8 VIM PDPN NF2 CDKN2A CALB2
43 meibomian cyst 29.7 KRT7 KRT20
44 fibrous histiocytoma 29.7 VIM PECAM1 MTAP
45 cystadenofibroma 29.7 WT1 KRT7 KRT5 CALB2
46 in situ carcinoma 29.7 PDPN KRT5 CDKN2A
47 thyroid gland follicular carcinoma 29.7 NKX2-1 KRT7 KRT19 CEACAM5
48 lymphangitis 29.7 PECAM1 PDPN NKX2-1 CEACAM5
49 pericardium cancer 29.6 WT1 MSLN KRT7 KRT5 KRT19 CEACAM5
50 pleomorphic carcinoma 29.6 PDPN NKX2-1 KRT7 CALB2

Graphical network of the top 20 diseases related to Benign Mesothelioma:



Diseases related to Benign Mesothelioma

Symptoms & Phenotypes for Benign Mesothelioma

UMLS symptoms related to Benign Mesothelioma:


snoring; coughing

MGI Mouse Phenotypes related to Benign Mesothelioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 CDKN2A GPC3 KRT19 MTAP NKX2-1 PDPN
2 digestive/alimentary MP:0005381 9.86 CDKN2A GPC3 KRT19 KRT5 NKX2-1 PDPN
3 embryo MP:0005380 9.81 BCL10 CDKN2A GPC3 KRT19 MTAP NF2
4 immune system MP:0005387 9.73 BCL10 CDKN2A GPC3 KRT19 KRT5 MTAP
5 respiratory system MP:0005388 9.36 CDKN2A GPC3 KRT19 MTAP NF2 NKX2-1

Drugs & Therapeutics for Benign Mesothelioma

Drugs for Benign Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 260)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vorinostat Approved, Investigational Phase 3 149647-78-9 5311
2
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
3
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
4
Raltitrexed Approved, Investigational Phase 3 112887-68-0 104758
5
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
6
Ipilimumab Approved Phase 3 477202-00-9
7
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
8
Nintedanib Approved Phase 2, Phase 3 656247-17-5 56843413
9
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
10
Ranpirnase Investigational Phase 3 196488-72-9
11
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
12 Histone Deacetylase Inhibitors Phase 3
13 Vitamin B 12 Phase 2, Phase 3
14 Vitamins Phase 2, Phase 3
15 Vitamin B12 Phase 2, Phase 3
16 Interferon-alpha Phase 3
17 Interferon alpha-2 Phase 3
18 Vinca Alkaloids Phase 3
19
Heparin Approved, Investigational Phase 2 9005-49-6 772 9812414
20
Vinblastine Approved Phase 2 865-21-4 13342 241903
21
Megestrol acetate Approved, Investigational, Vet_approved Phase 1, Phase 2 595-33-5 11683
22
Zoledronic Acid Approved Phase 2 118072-93-8 68740
23
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
24
Axitinib Approved, Investigational Phase 1, Phase 2 319460-85-0 6450551
25
Belinostat Approved, Investigational Phase 2 866323-14-0
26
Pancrelipase Approved, Investigational Phase 2 53608-75-6
27
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
28
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
29
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
30
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
31
Adenosine Approved, Investigational Phase 1, Phase 2 58-61-7 60961
32
Pentostatin Approved, Investigational Phase 1, Phase 2 53910-25-1 40926 439693
33
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
34
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
35
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
36
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
38
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
39
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
40
Epirubicin Approved Phase 2 56420-45-2 41867
41
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
42
Ranitidine Approved, Withdrawn Phase 2 66357-59-3, 66357-35-5, 82530-72-1 3001055
43
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
44
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
45
Sodium citrate Approved, Investigational Phase 2 68-04-2
46
Tamoxifen Approved Phase 2 10540-29-1 2733526
47
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
48
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
49
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
50
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1

Interventional clinical trials:

(show top 50) (show all 415)
# Name Status NCT ID Phase Drugs
1 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Recruiting NCT03655834 Phase 4 Pemetrexed
2 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Recruiting NCT03655821 Phase 4 Pemetrexed
3 ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
4 A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
5 Prospective Randomised Controlled Trial of Video-Assisted Thoracoscopic (VAT) Cytoreductive Pleurectomy Compared to Talc Pleurodesis in Patients With Suspected or Proven Malignant Mesothelioma Completed NCT00821860 Phase 3
6 NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM) Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
7 A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
8 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy Completed NCT00128102 Phase 3 Vorinostat;Placebo
9 A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma Completed NCT00006231 Phase 3
10 A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
11 A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
12 Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma Completed NCT00004920 Phase 3 cisplatin;raltitrexed
13 Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies Completed NCT02349412 Phase 3
14 A Randomized, Open-Label Phase II/III Study With Dendritic Cells Loaded With Allogeneic Tumour Cell Lysate (PheraLys) in Subjects With Mesothelioma as Maintenance Treatment (MesoPher) After Chemotherapy Recruiting NCT03610360 Phase 2, Phase 3 MesoPher
15 Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) Recruiting NCT04158141 Phase 3 Carboplatin;Cisplatin;Pemetrexed;Pemetrexed Disodium
16 Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study) Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
17 A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma Recruiting NCT03762018 Phase 3 Carboplatin;Pemetrexed;Bevacizumab;Atezolizumab
18 A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma Recruiting NCT03710876 Phase 3 Celecoxib Oral Product;Gemcitabine
19 DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial Recruiting NCT04334759 Phase 3 Durvalumab;Standard Chemotherapy
20 CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma Active, not recruiting NCT03063450 Phase 3 Nivolumab
21 A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Active, not recruiting NCT02784171 Phase 2, Phase 3 Cisplatin;Pemetrexed;Pembrolizumab
22 A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
23 A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Active, not recruiting NCT02899299 Phase 3 Pemetrexed;Cisplatin;Carboplatin
24 PIT: A Phase III Randomised Trial of Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Following Invasive Chest Wall Intervention Terminated NCT01604005 Phase 3
25 LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma Terminated NCT01907100 Phase 2, Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
26 A Randomized Phase III Trial to Compare the Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication for Mesothelioma or Other Pathologies Withdrawn NCT02511600 Phase 3
27 Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors: a Single Arm Phase 2 Study Unknown status NCT03647956 Phase 2 Atezolizumab;Bevacizumab;Carboplatin;Pemetrexed
28 "Phase II Study: Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma " Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
29 A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothelioma Unknown status NCT01649024 Phase 2 Tremelimumab
30 Four Versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelioma; a Randomized Phase II Study Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
31 A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
32 A Phase II Study of Milataxel (TL139) Administered Orally in Patients With Malignant Mesothelioma Unknown status NCT00685204 Phase 2 Milataxel
33 A Phase II Study of the Association of Glivec® (Imatinib Mesylate, Formerly Known as STI 571) Plus Gemzar® (Gemcitabine) in Patients With Unresectable, Refractory, Malignant Mesothelioma Expressing Either PDGFR-Beta or C-Kit Unknown status NCT00551252 Phase 2 Imatinib mesylate plus Gemcitabine
34 A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012 Unknown status NCT01655888 Phase 2 Tremelimumab
35 Cisplatin With Either Alimta or Gemcitabine in Long Infusion for Mesothelioma: A Randomised Phase II Trial (AGILI Trial) Unknown status NCT01281800 Phase 2
36 Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-based Chemotherapy Unknown status NCT00794859 Phase 2 Sorafenib
37 A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
38 A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1 Unknown status NCT02588131 Phase 2 tremelimumab plus MEDI4736
39 A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma Unknown status NCT02568449 Phase 2 Nintedanib
40 A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma Unknown status NCT02139904 Phase 2 Vinorelbine
41 Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
42 Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
43 Randomized Feasibility Study Of Active Symptom Control With Or Without Chemotherapy In The Treatment Of Patients With Mesothelioma Unknown status NCT00030459 Phase 2 cisplatin;mitomycin C;vinblastine sulfate;vinorelbine tartrate
44 Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma. Unknown status NCT01869023 Phase 2 Gemcitabine;Cisplatin
45 A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
46 Phase I/II Study of High-Dose Megestrol in Breast or Endometrial Carcinoma or Mesothelioma Unknown status NCT00002465 Phase 1, Phase 2 megestrol acetate
47 Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study Unknown status NCT01291420 Phase 1, Phase 2
48 Cytoreductive Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy for the Treatment of Peritoneal Carcinomatosis From Gastrointestinal Cancer: an Open Label, Randomized, Prospective, Phase 2 Clinical Trial Unknown status NCT00454519 Phase 2
49 A Pilot Phase 2 Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Advanced Malignant Mesothelioma Completed NCT01204203 Phase 2 Zometa
50 Pilot Study of the Feasibility of Intrapleural Photodynamic Therapy in a Multimodal Treatment Combining Extended Pleurectomy/Decortication, Adjuvant Chemotherapy and Prophylactic Radiotherapy in Patients With Malignant Pleural Mesothelioma Completed NCT02662504 Phase 2 Adjuvant chemotherapy

Search NIH Clinical Center for Benign Mesothelioma

Cochrane evidence based reviews: mesothelioma

Genetic Tests for Benign Mesothelioma

Anatomical Context for Benign Mesothelioma

MalaCards organs/tissues related to Benign Mesothelioma:

40
Testis, Lung, T Cells, Thyroid, Breast, Lymph Node, Heart

Publications for Benign Mesothelioma

Articles related to Benign Mesothelioma:

(show top 50) (show all 15652)
# Title Authors PMID Year
1
Lack of Bcl10 mutations in testicular germ cell tumours and derived cell lines. 6
10408400 1999
2
Lack of BCL10 mutations in germ cell tumors and B cell lymphomas. 6
10380920 1999
3
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 6
9989495 1999
4
Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. 6
8298644 1993
5
Ultrastructure and observations on the histogenesis of mesotheliomas, "adenomatoid tumors", of the female genital tract. 6
4332312 1972
6
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. 54 61
19744744 2010
7
Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. 61 54
20142415 2010
8
Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model. 61 54
20072072 2010
9
Serum level of expressed in renal carcinoma (ERC)/ mesothelin in rats with mesothelial proliferative lesions induced by multi-wall carbon nanotube (MWCNT). 54 61
20371980 2010
10
Expression of podoplanin and calretinin in meningioma: an immunohistochemical study. 61 54
20425044 2010
11
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. 61 54
20146302 2010
12
Survey of British pathologists' performance of mesothelioma post-mortems. 54 61
20092958 2010
13
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. 54 61
20075387 2010
14
The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy. 54 61
20051956 2010
15
In vitro and in vivo characterization of highly purified human mesothelioma derived cells. 54 61
20175889 2010
16
Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. 61 54
20131968 2010
17
A bipartite butyrate-responsive element in the human calretinin (CALB2) promoter acts as a repressor in colon carcinoma cells but not in mesothelioma cells. 61 54
19998412 2010
18
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. 54 61
20103626 2010
19
CCL2 blockade augments cancer immunotherapy. 54 61
20028856 2010
20
[Malignant peritoneal mesothelioma]. 54 61
20445731 2010
21
Up-regulation of Bcl-xl by hepatocyte growth factor in human mesothelioma cells involves ETS transcription factors. 54 61
19834061 2009
22
Malignant pleural mesothelioma: an update on biomarkers and treatment. 61 54
19736192 2009
23
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. 61 54
19299498 2009
24
Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. 54 61
19662092 2009
25
Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. 54 61
19671873 2009
26
SV40-induced expression of calretinin protects mesothelial cells from asbestos cytotoxicity and may be a key factor contributing to mesothelioma pathogenesis. 61 54
19435792 2009
27
Osteopontin modulates malignant pleural mesothelioma cell functions in vitro. 54 61
19528482 2009
28
Functional inactivation of NF2/merlin in human mesothelioma. 61 54
18835652 2009
29
Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy. 54 61
19478948 2009
30
Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. 54 61
19285954 2009
31
Glypican-3 regulates migration, adhesion and actin cytoskeleton organization in mammary tumor cells through Wnt signaling modulation. 61 54
18404367 2009
32
Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma. 54 61
19516197 2009
33
Calretinin: diagnostic utility in the female genital tract. 61 54
19550372 2009
34
Clinical utility of diagnostic markers for malignant pleural mesothelioma. 61 54
19522163 2009
35
Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers. 54 61
19261093 2009
36
A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. 61 54
19179889 2009
37
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. 61 54
18618081 2009
38
Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats. 54 61
19128473 2009
39
Pleomorphic carcinoma of the lung expressing podoplanin and calretinin. 61 54
19067851 2008
40
Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. 61 54
19020717 2008
41
ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma. 61 54
19192652 2008
42
YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. 54 61
18725387 2008
43
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. 54 61
18511708 2008
44
Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. 54 61
18281122 2008
45
The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. 54 61
17916095 2008
46
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. 54 61
18670302 2008
47
Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts. 54 61
18360826 2008
48
The value of immunohistochemical expression of TTF-1, CK7 and CK20 in the diagnosis of primary and secondary lung carcinomas. 54 61
18626520 2008
49
Malignant mesothelioma 2008. 61 54
18520263 2008
50
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. 54 61
18327208 2008

Variations for Benign Mesothelioma

ClinVar genetic disease variations for Benign Mesothelioma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 WT1 NM_024426.6(WT1):c.1036A>G (p.Ser346Gly) SNV Pathogenic 3499 rs121907908 GRCh37: 11:32421571-32421571
GRCh38: 11:32400025-32400025
2 BCL10 NM_003921.5(BCL10):c.136del (p.Ile46fs) Deletion Pathogenic 6263 rs387906351 GRCh37: 1:85736511-85736511
GRCh38: 1:85270828-85270828
3 BCL10 NM_003921.5(BCL10):c.499dup (p.Ser167fs) Duplication Pathogenic 6250 rs387906350 GRCh37: 1:85733512-85733513
GRCh38: 1:85267829-85267830

Expression for Benign Mesothelioma

Search GEO for disease gene expression data for Benign Mesothelioma.

Pathways for Benign Mesothelioma

Pathways related to Benign Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.91 KRT7 KRT5 KRT20 KRT19
2 11.66 VIM PDPN NF2 KRT7 KRT5 KRT20
3
Show member pathways
11.29 VIM KRT7 KRT5 KRT19

GO Terms for Benign Mesothelioma

Cellular components related to Benign Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 WT1 VIM PDPN NF2 MTAP KRT7
2 intermediate filament GO:0005882 9.02 VIM KRT7 KRT5 KRT20 KRT19

Biological processes related to Benign Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.55 WT1 PDPN NF2 GPC3 CDKN2A
2 lung development GO:0030324 9.43 PDPN NKX2-1 GPC3
3 keratinization GO:0031424 9.26 KRT7 KRT5 KRT20 KRT19
4 cornification GO:0070268 8.92 KRT7 KRT5 KRT20 KRT19

Molecular functions related to Benign Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural constituent of cytoskeleton GO:0005200 8.92 VIM KRT5 KRT20 KRT19

Sources for Benign Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....